Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Quest Diagnostics

Share:
Related DGX
Benzinga's Top Downgrades
Quest Diagnostics Reveals Planned Senior Notes Offering For $500M
Brexit kills the value trade, buy 'Stable Growers' - RBC (Seeking Alpha)

In a report published Monday, Jefferies & Company reiterated its Hold rating on Quest Diagnostics (NYSE: DGX), but lowered its price target from $63.00 to $59.00.

Jefferies noted, “We continue to have a neutral view on DGX given our belief that ongoing weakness in lab volumes will persist and keep the stock rangebound near-term. While we are optimistic that mgmt's efforts to restructure operations and rationalize expenses will achieve their targets, we recognize that this process, which could be the key catalyst for the stock, will take time to complete.”

Quest Diagnostics closed on Friday at $57.94.

Latest Ratings for DGX

DateFirmActionFromTo
Jun 2016Jyske BankDowngradesSell
Mar 2016Credit SuisseInitiates Coverage onNeutral
Mar 2016Mizuho SecuritiesUpgradesNeutralBuy

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (DGX)

View Comments and Join the Discussion!